Cong Qiu Chu, MD
Rheumatology · Portland, ORNPI 1780625780
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,650 of the $5,214 with a category attached, or 89.2%. Johnson & Johnson accounts for 92.4% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,280, more than ten times the $155 reported in 2019.
Across 12 payments — averaging $434.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- Pharming Healthcare, Inc.$125
- Regeneron Healthcare Solutions, Inc.$90
- Sanofi$90
- Bristol Myers Squibb$65
- GSK$14
- plus $13 from 1 others
Across 56 payments — averaging $6802.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$167K
- Genentech, Inc.$60K
- Chugai Pharmaceutical Co., Ltd.$48K
- Eli Lilly$40K
- Sanofi US Services Inc.$34K
- AbbVie$15K
- plus $17K from 3 others
What the payments were for
- Consulting fees$4,65089%
- Travel & lodging$250%
- Food & beverage$4368%
- Education$1032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $4,818 |
| Pharming Healthcare, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $90 |
| Sanofi | 1 | $90 |
| Bristol Myers Squibb | 1 | $65 |
| GSK | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$4,793
- STELARA$750
- SIMPONI ARIA$750
- JOENJA$125
How this compares
$5,214 in reported general payments places this provider in the 85th percentile of 79 rheumatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 91 | $1,020 |
| Hydroxychloroquine Sulfate | 29 | $928 |
| MethotrexateMethotrexate Sodium | 34 | $913 |
| Colchicine | 18 | $543 |
| Folic Acid | 12 | $146 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Portland
- Atulya DeodharPortland$694K
- Rosario BonafedePortland$148K
- James RosenbaumPortland$84K
- Kelly PortnoffPortland$13K
- Neha Rich-GargPortland$11K
- Rashmi ShahPortland$5K
- Caroline McCulleyPortland$4K
- John GriffinPortland$2K
- Whitney Elg-SalsmanPortland$981
- Anne VettoPortland$337
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.